Journal
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
Volume 3, Issue 5, Pages 487-498Publisher
SPRINGER
DOI: 10.1007/s12265-010-9201-y
Keywords
Cardiovascular Disease; Hydrogen Sulfide; Therapeutics; Drug Development; Myocardial Ischemia; Atherosclerosis; Hypertension
Funding
- NIH [5R01 HL092141-02, 1R01 HL093579-01A1]
- Carlyle Fraser Heart Center (CFHC) of Emory University Hospital Midtown
Ask authors/readers for more resources
The physiological role of the gaseous signaling molecule hydrogen sulfide (H2S) was first realized in the mid-1990s with the work of Abe and Kimura. Since then, it has become evident that this endogenous gas is extremely important in the homeostasis of the cardiovascular system and the pathogenesis of cardiovascular disease. Several biotechnology companies have developed and are developing H2S-based therapeutic compounds, and there are ongoing clinical trials investigating the therapeutic potential of H2S. Several organic and chemical compounds that are known H2S donors have the potential to be developed into effective H2S-based therapeutic agents. This review will provide a historical and current perspective on the role(s) of H2S in the cardiovascular system and the current state of development and future outlook of H2S-based therapies for cardiovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available